Arvinas Doses First Patient in Phase 1/2 Trial for Immuno-Oncology Candidate ARV-6723
Event summary
- Arvinas dosed the first patient in its Phase 1/2 trial for ARV-6723, an oral PROTAC targeting HPK1 in advanced solid tumors.
- ARV-6723 is Arvinas’ first immuno-oncology candidate and the first HPK1 PROTAC degrader in U.S. clinical trials.
- The trial (NCT07749586) will evaluate ARV-6723 as monotherapy and in combination with pembrolizumab.
- Preclinical data showed ARV-6723 demonstrated antitumor activity in anti-PD-1-resistant models.
The big picture
Arvinas’ entry into immuno-oncology with ARV-6723 marks a strategic shift toward addressing resistance to immunotherapy, a significant unmet need in oncology. The trial’s focus on HPK1 degradation could differentiate Arvinas in a competitive landscape dominated by traditional immune checkpoint inhibitors. Success here would validate the company’s PROTAC platform beyond its existing collaborations with Pfizer and Rigel Pharmaceuticals.
What we're watching
- Clinical Efficacy
- Whether ARV-6723 can demonstrate meaningful antitumor effects in patients, particularly in anti-PD-1-resistant models.
- Combination Strategy
- The pace at which Arvinas advances ARV-6723 in combination with pembrolizumab and other immune checkpoint inhibitors.
- Pipeline Expansion
- How Arvinas leverages the success of ARV-6723 to expand its immuno-oncology portfolio.
Related topics